(Q27684428)

ChEBI release 2020-05-28

8

0 references

Junko Mikuni

Junko Mikuni

9

0 references

Hitomi Yuki

Hitomi Yuki

2

0 references

Osamu Ohara

Osamu Ohara

23

0 references

Shigeyuki Yokoyama

Shigeyuki Yokoyama

28

0 references

Yuho Najima

Yuho Najima

13

0 references

Noriko Handa

10

Noriko Handa

0 references

Motoaki Wakiyama

15

Motoaki Wakiyama

0 references

Yuri Tomabechi

14

Yuri Tomabechi

0 references

Teruki Honma

6

Teruki Honma

0 references

Mitsuo Kuratani

3

Mitsuo Kuratani

0 references

author name string

Yoriko Saito

1

0 references

Yoshinobu Hashizume

4

0 references

Shinsuke Takagi

5

0 references

Akiko Tanaka

7

0 references

Ikuko Ogahara

11

0 references

Akiko Sone

12

0 references

Naoyuki Uchida

16

0 references

Mariko Tomizawa-Murasawa

17

0 references

Akiko Kaneko

18

0 references

Satoshi Tanaka

19

0 references

Nahoko Suzuki

20

0 references

Hiroshi Kajita

21

0 references

Yuki Aoki

22

0 references

Leonard D Shultz

24

0 references

Takehiro Fukami

25

0 references

Toshio Goto

26

0 references

Shuichi Taniguchi

27

0 references

Fumihiko Ishikawa

Science Translational Medicine

29

0 references

language of work or name

English

0 references

publication date

17 April 2013

0 references

published in

0 references

volume

5

0 references

issue

181

0 references

page(s)

181ra52

0 references

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

A novel Pim-1 kinase inhibitor targeting residues that bind the substrate peptide

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

FLT3 as a therapeutic target in AML: still challenging after all these years

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

ChEMBL: a large-scale bioactivity database for drug discovery

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

Virtual screening strategies in drug discovery

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

The CCP4 suite: programs for protein crystallography

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

Coot: model-building tools for molecular graphics

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

Crystal structure of the Src family tyrosine kinase Hck

21 April 2017

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004387

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays

21 April 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 April 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Genetic abnormalities and challenges in the treatment of acute myeloid leukemia

21 April 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Anthracycline dose intensification in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Leukemia stem cells and microenvironment: biology and therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Stem cell gene expression programs influence clinical outcome in human leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Src family kinases: regulation of their activities, levels and identification of new pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Signal transduction pathways that contribute to myeloid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Humanized mice in translational biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

A critical role for Lyn in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Antileukemic activity of rapamycin in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Stem cell c-KIT and HOXB4 genes: critical roles and mechanisms in self-renewal, proliferation, and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Signaling of c-kit in dendritic cells influences adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

In silico design of protein kinase inhibitors: successes and failures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Processing of X-ray diffraction data collected in oscillation mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004387